MaasFlex: Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Oxidation, Glucose Metabolism and Muscle Mitochondrial Function in Individuals With Impaired Glucose Homeostasis
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Glucose intolerance; Glucose metabolism disorders; Insulin resistance
- Focus Therapeutic Use
- Acronyms MaasFlex
- 10 Sep 2019 Planned End Date changed from 1 Jan 2020 to 1 Oct 2020.
- 10 Sep 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Oct 2020.
- 22 Mar 2019 Status changed from not yet recruiting to recruiting.